摘要
目的观察舒利迭[沙美特罗/替卡松粉吸入剂(50μg/100μg)]在慢性阻塞性肺疾病(COPD)缓解期中的疗效。方法我院呼吸科就诊的中重度COPD患者92例,随机分为治疗组和对照组。对照组给予常规治疗,治疗组在此基础上给予吸入舒利迭(50μg/100μg)。结果治疗组的总有效率显著高于对照组,两组疗效比较差异有显著性(P<0.01);治疗组在观察期间临床症状、运动耐力较对照组明显改善、因急性发作住院的次数明显低于对照组;治疗组的FEV1、FVC治疗后显著高于对照组(P<0.05)。结论在中重度COPD缓解期中应用舒利迭(50μg/100μg)的治疗能减少COPD急性发作次数,提高患者肺功能,明显的改善症状与体征。使用安全,值得在临床上推广。
Objective To observe the effects of seretide （salmeterel） and fluticasone propionate powder inhalants （50 μg/100 μg） in chronic obstructive pulmonary disease （COPD） during the mitigation. Methods In the treatment of moderate and severe 92 patients with COPD in the Department of Respiratory Diseases in our hospital, the patients were randomly divided into treatment and control groups. The control group was given conventional treatment, while the treatment group was given the aspiration for seretide （50 μg/100 μg） on the basis of the conventional treatment. Results The total efficiency of the treatment group is significantly higher than that of the control group. The comparison of different effects between the two groups was significant （P 〈 0. 01 ）. The clinical symptoms in the treatment group, and exercise tolerance during the period of observation, were significantly improved more than those of the control greup, meanwhile the number of acute hospitalization was obviously lower than the control group. The values of FEV1, FVC in the treatment group after treatment were significantly higher than in the control group （ P 〈 0. 05 ）. Conclusion Seretide （50 μg/100 μg） in the treatment of moderate and severeCOPD during the mitigation can reduce the number of outbreaks of acute COPD and enhance patients with lung function, and has obvious improvement of their cough, phlegm, symptoms of short breath and lung wet-La sign. Due to its safety, it is worth being recommended to use in clinical practice.
出处
《临床肺科杂志》
2009年第4期430-431,共2页
Journal of Clinical Pulmonary Medicine
关键词
舒利迭
慢性阻塞性肺疾病
缓解期
临床观察
seretide
chronic obstructive pulmonary disease
remission
clinical observation
